acf/google-ad-placement

<ul>
	<li><strong>Intra-Cellular Therapies Inc</strong>&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/itci#NASDAQ" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">ITCI</a>)&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/02/g19770043/intra-cellular-therapies-applies-for-fda-approval-of-caplyta-lumateperone-for-the-treatment-of-bip" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">submits CAPLYTA (lumateperone) supplemental marketing application</a>&nbsp;to the FDA to treat depressive episodes associated with bipolar I or II disorder in adults.</li>
	<li>The application seeks approval for two indications of CAPLYTA; as monotherapy and as adjunctive therapy with lithium or valproate.</li>
	<li>The Company anticipates an FDA target action date for the application in the second half of 2021.</li>
	<li>CAPLYTA is indicated for the treatment of schizophrenia in adults.</li>
	<li><strong>Price Action:</strong>&nbsp;ITCI decreased 1.70% at $38.84 in market trading hours on the last check Monday.</li>
</ul>


Biotech

News

General

Comments